ZM C101
Alternative Names: ZM-C101Latest Information Update: 06 Jan 2023
At a glance
- Originator Medicinal Bioconvergence Research Center
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Amino acyl tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Colorectal cancer
Most Recent Events
- 15 Dec 2022 Early research in Colorectal cancer in South Korea (unspecified route) before December 2022 (ZYMEDI pipeline, December 2022)